

# CHEMO PHARMA LABORATORIES LIMITED

EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001.

TEL: OFF. 91-22-22078381, 22078382 • FAX: 91-22-22074294

www.thechemopharmalaboratoriesltd.com

EMAIL: contact@thechemopharmalaboratoriesltd.com / chemopharma2011@gmail.com

## UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30TH JUNE, 2013

(Rs in '000)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30th June 2013	31st March 2013	30th June 2012	31st March, 2013
		Unaudited	Audited	Unaudited	Audited
1	<b>Income from Operations</b>				
	(a) Net Sales/ Income from Operations (Net of excise duty)	-	-	-	-
	(b) Other Operating Income	631	2,284	189	2,698
	<b>Total Income from operations (net)</b>	<b>631</b>	<b>2,284</b>	<b>189</b>	<b>2,698</b>
2	<b>Expenses</b>				
	(a) Cost of materials consumed	-	-	-	-
	(b) Purchases of Stock-in-trade	-	-	-	-
	(c) Change in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	(d) Employee benefits expenses	41	36	34	28
	(e) Depreciation and amortisation expense	11	15	15	62
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	58	14	28	685
	i) Professional Charges	264	39	417	88
	ii) Share Registry Expenses	-	50	-	48
	<b>Total Expenses</b>	<b>374</b>	<b>154</b>	<b>494</b>	<b>911</b>
3	<b>Profit / Loss from Operation before other income, Finance cost and exceptional items (1-2)</b>	<b>257</b>	<b>2,130</b>	<b>(305)</b>	<b>1,787</b>
4	<b>Other Income</b>	-	-	-	-
5	<b>Profit / Loss from ordinary activities before Finance cost and exceptional items (3+4)</b>	<b>257</b>	<b>2,130</b>	<b>(305)</b>	<b>1,787</b>
6	<b>Finance Costs</b>	-	-	-	-
7	<b>Profit / Loss from ordinary activities after Finance cost but before exceptional items (5+6)</b>	<b>257</b>	<b>2,130</b>	<b>(305)</b>	<b>1,787</b>
8	<b>Exceptional Items</b>	-	-	-	-
9	<b>Net Profit/(Loss) from ordinary activities before tax (7+8)</b>	<b>257</b>	<b>2,130</b>	<b>(305)</b>	<b>1,787</b>
10	<b>Tax expenses</b>	-	-	-	355
11	<b>Net Profit/(Loss) from ordinary activities after tax (9+10)</b>	<b>257</b>	<b>2,130</b>	<b>(308)</b>	<b>1,432</b>
12	<b>Extra ordinary items (net of tax expenses Ra. )</b>	-	-	-	-
13	<b>Net Profit/ (Loss) for the period (11+12)</b>	<b>257</b>	<b>2,130</b>	<b>(305)</b>	<b>1,432</b>
14	<b>Share of Profit/ (Loss) of associate*</b>	-	-	-	-
15	<b>Minority interest *</b>	-	-	-	-
16	<b>Net Profit/ (Loss) after taxes, minority interest and share of profit / (loss) of associates (13+14+15)*</b>	<b>257</b>	<b>2,130</b>	<b>(308)</b>	<b>1,432</b>
17	<b>Paid-up equity share Capital (face value of Ra. 10/- each)</b>	<b>15,000</b>	<b>15,000</b>	<b>15,000</b>	<b>15,000</b>
18	<b>Reserves excluding revaluation reserve as per balance sheet of previous accounting year</b>	<b>31,093</b>	<b>31,093</b>	<b>29,661</b>	<b>31,093</b>
19	<b>i) Earning per share (before extraordinary items) of Ra. 10/- each) (not annualised) :</b>				
	(a) Basic	0.17	1.42	(0.20)	0.95
	(b) Diluted				
19	<b>ii) Earning per share (after extraordinary items) of Ra. 10/- each) (not annualised) :</b>				
	(a) Basic	0.17	1.42	(0.20)	0.95
	(b) Diluted				



**CHEMO PHARMA LABORATORIES LIMITED**EMPIRE HOUSE, 3<sup>RD</sup> FLOOR, 214, DR. D. N. ROAD, FORT, MUMBAI - 400 001.

TEL: OFF. 91-22-22078381, 22078382 • FAX: 91-22-22074294

www.thechemopharmalaboratoriesltd.com

EMAIL: contact@thechemopharmalaboratoriesltd.com / chemopharma2011@gmail.com

<b>A PARTICULARS OF SHAREHOLDING</b>					
1	Public Shareholding				
	- Number of shares	1,081,719	1,081,719	1,028,858	1,081,719
	- Percentage of shareholding	72.11	72.11	68.59	72.11
19	Promoters and Promoter Group shareholding**				
	a) Pledged/Encumbered				
	- Number of shares	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
	- Percentage of shares (as a % of the total share capital of company)	NIL	NIL	NIL	NIL
	b) Non-Encumbered				
	- Number of shares	418,281	418,281	471,142	418,281
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100	100	100	100
	- Percentage of shares (as a % of the total share capital of company)	27.89	27.89	31.41	27.89

**Note :**

1. The above unaudited financial results have been taken on record by Audit Committee in their meeting on 26.07.2013 and also approved by the Board in their meeting held on 26.07.2013
2. Separate segment reporting is not applicable to the company.

Place : Mumbai  
Date : 26th July 2013



By Order of the Board  
For Chemo - Pharma Laboratories Limited

*Ashok B.*

Director


**BATLIBOI & PUROHIT**  
**CHARTERED ACCOUNTANTS****REVIEW REPORT TO THE BOARD OF DIRECTORS OF****CHEMO PHARMA LABORATORIES LIMITED**

We have reviewed the accompanying statement of unaudited financial results of **Chemo Pharma Laboratories Ltd.**, ("the Company") for the quarter ended 30<sup>th</sup> June 2013 except for the disclosures regarding "Public Shareholding" and "Promoter and Promoter Group Shareholding" which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information performed by the independent Auditor of the entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 Interim Financial Reporting, [notified pursuant to the Company's (Accounting Standards) Rules, 2006 as (amended)] and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For BATLIBOI & PUROHIT**  
Chartered Accountants  
Firm Reg No. 101048W

  
**Paresh A. Chokshi**  
Partner  
Membership No. 33597

Place : Mumbai  
Dated : 26/07/2013